Korean J Med.  2012 Sep;83(3):400-404.

A Case of Bowen's Disease During Adalimumab Treatment for Felty's Syndrome

• Park HY
• Kim HS
• Hong R

Abstract

Felty's syndrome is an uncommon condition characterized by the combination of rheumatoid arthritis (RA), splenomegaly, and neutropenia. Disease-modifying anti-rheumatic drugs and biologic agents have been used to treat early RA to achieve remission. Anti-tumor necrosis factor (TNF)-alpha agents are effective for controlling the disease; however, some studies have suggested the possibility of adverse effects such as increased frequency of infection or malignancy. Bowen's disease, known as squamous cell carcinoma in situ, is a skin cancer that can be caused by sun exposure, arsenic ingestion, human papilloma virus, skin damage, and prolonged immunosuppression. We report the case of a 64-year-old female diagnosed with Bowen's disease during treatment with an anti-TNF agent for Felty's syndrome with a review of the literature.

Keyword

Anti-tumor necrosis factor agent; Bowen's disease; Felty's syndrome

MeSH Terms

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Arsenic
Arthritis, Rheumatoid
Bowen's Disease
Carcinoma, Squamous Cell
Eating
Felty Syndrome
Female
Humans
Immunosuppression
Middle Aged
Necrosis
Neutropenia
Papilloma
Skin
Skin Neoplasms
Solar System
Splenomegaly
Viruses
Adalimumab
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Arsenic